mercoledì, 25 novembre 2020
Medinews
20 Febbraio 2018

ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer

February 16, 2018 – As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) updated guideline on molecular testing for selection of lung cancer patients for targeted tyrosine kinase inhibitor treatment. The endorsement was based on an ASCO expert panel … (leggi tutto)

TORNA INDIETRO